US Patent

US8071643 — Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Composition of Matter · Assigned to Nabriva Therapeutics AG · Expires 2033-03-25 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a pleuromutilin derivative compound, specifically a compound of general formula (I), as described in the USPTO abstract.

USPTO Abstract

A pleuromutilin derivative compound of general formula (I)

Drugs covered by this patent

Patent Metadata

Patent number
US8071643
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-03-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Nabriva Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.